Developing a Model for Non-Invasive Detection of Gliomas Using MicroRNA Biomarkers
Advisor(s)
Dr. Sowmya Anjur; Illinois Mathematics and Science Academy
Discipline
Biology
Start Date
21-4-2021 9:10 AM
End Date
21-4-2021 9:25 AM
Abstract
Current methods of diagnosing brain tumors often include imaging tests accompanied by a biopsy involving the surgical removal of a tissue sample to determine if the tumor is cancerous. However, one area of non-invasive cancer detection that is currently undergoing research and shows great diagnostic potential are the presence of microRNA biomarkers in the blood to predict and diagnose a brain tumor before the onset of symptoms.
Through gathering and analyzing existing data on the roles of microRNA 21 (miRNA-21) in the development and detection of different gliomas, we can create a predictive model for the presence of specific types/WHO grades of gliomas based on the levels of miRNA-21 in the patient’s blood, providing valuable insight into the potential diagnosis and prognosis of brain tumors using non-invasive procedures. Specifically, the model takes into account the fold-change of normal levels of miRNA-21 in the blood to predict the likelihood of the varying grades of astrocytomas accounting for these changes.
Developing a Model for Non-Invasive Detection of Gliomas Using MicroRNA Biomarkers
Current methods of diagnosing brain tumors often include imaging tests accompanied by a biopsy involving the surgical removal of a tissue sample to determine if the tumor is cancerous. However, one area of non-invasive cancer detection that is currently undergoing research and shows great diagnostic potential are the presence of microRNA biomarkers in the blood to predict and diagnose a brain tumor before the onset of symptoms.
Through gathering and analyzing existing data on the roles of microRNA 21 (miRNA-21) in the development and detection of different gliomas, we can create a predictive model for the presence of specific types/WHO grades of gliomas based on the levels of miRNA-21 in the patient’s blood, providing valuable insight into the potential diagnosis and prognosis of brain tumors using non-invasive procedures. Specifically, the model takes into account the fold-change of normal levels of miRNA-21 in the blood to predict the likelihood of the varying grades of astrocytomas accounting for these changes.